H.C. Wainwright Thinks Caladrius Biosciences’ Stock is Going to Recover


H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Caladrius Biosciences (CLBS) today and set a price target of $18.50. The company’s shares closed yesterday at $2.68, close to its 52-week low of $2.16.

Pantginis said:

“Valuation and risks to price target achievement; only need a little to be potentially quite meaningful. We reiterate our Buy rating and $18.50 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. As part of our valuation projections, we make the following assumptions, which we also believe provide additional levels of conservatism to our projections. Our projections for CLBS12 only includes our projections for the market in Japan, which we project the company would market for a 15% royalty.”

According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -12.5% and a 29.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Iovance Biotherapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Caladrius Biosciences with a $10.42 average price target.

See today’s analyst top recommended stocks >>

Based on Caladrius Biosciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $4.37 million. In comparison, last year the company had a GAAP net loss of $4.08 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts